메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
이정수 (Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea.Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangs) 김영범 (Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.) Shin Kihyuk (Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea.) 김훈수 (부산대학교) Ko Hyun-chang (Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea.) Kim Moon-Bum (Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.Department of Dermatology, Pusan National University Hospital, Busan, Korea.) Kim Byung Soo (Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea.Department of Dermatology, Pusan National University Hospital, Busan, Korea.Biomedical Research Institu)
저널정보
대한천식알레르기학회(구 대한알레르기학회) Allergy, Asthma & Immunology Research AAIR Vol.16 No.5
발행연도
2024.9
수록면
546 - 554 (9page)
DOI
10.4168/aair.2024.16.5.546

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Prurigo nodularis (PN) is a chronic neuroinflammatory dermatosis with severe pruritus that has limited efficacy in various conventional treatments. This study investigated the outcomes of upadacitinib treatment in patients with refractory PN. A prospective study was conducted to screen for potential chronic infections prior to treatment. Upadacitinib was administered at a daily dose of 15 mg for 24 weeks, and the treatment response was assessed using the itch Numeric Rating Scale (NRS), investigator’s Global Assessment (IGA), and Dermatology Life Quality Index (DLQI). Adverse events were monitored at each visit. Ten patients, with an average age of 48.8 years, were included in the study. All participants were treated with systemic cyclosporine before receiving upadacitinib, which yielded limited responses. At baseline, the mean prurigo severity scores assessed using the IGA, DLQI, and itch NRS were 3.4, 17.8, and 8.1, respectively; after 24 weeks of treatment, these scores significantly reduced to 1.0, 0.6, and 0.8, respectively. No severe adverse effects were observed. In conclusion, upadacitinib could be considered an alternative therapeutic option with good tolerability for refractory PN.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

최근 본 자료

전체보기

댓글(0)

0